Palvella Therapeutics (PVLA) Income from Non-Controlling Interests (2017 - 2024)
Palvella Therapeutics' (PVLA) quarterly Income from Non-Controlling Interests came in at -$1000.0 in Q1 2024, down 101.43% year-on-year from $70000.0 in Q2 2023, and down 150.0% on a QoQ basis from $2000.0 in Q3 2023.
Palvella Therapeutics (PVLA) Income from Non-Controlling Interests (2017 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 7 years of Income from Non-Controlling Interests data on file, last reported at -$1000.0 in Q1 2024.
- On a quarterly basis, Income from Non-Controlling Interests fell 101.43% year-over-year to -$1000.0 in Q1 2024; TTM through Sep 2024 was -$1000.0, a 98.77% increase from a year earlier, with the FY2023 full-year figure at $74000.0, up 201.37% from the prior year.
- Income from Non-Controlling Interests for Q1 2024 stood at -$1000.0, down from $2000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for PVLA reached as high as $319000.0 in Q4 2020 and fell as low as -$350000.0 in Q3 2020.
- Historically, Income from Non-Controlling Interests has averaged $5833.3 across 4 years, with a median of $500.0 in 2023.
- Across the five-year window, Income from Non-Controlling Interests plunged 193.58% in 2020 and surged 468.42% in 2023, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $319000.0 in 2020, then plunged by 148.59% to -$155000.0 in 2022, then jumped by 101.29% to $2000.0 in 2023, then slumped by 150.0% to -$1000.0 in 2024.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$1000.0 in Q1 2024, $2000.0 in Q3 2023, and $2000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.86 Bn | 1.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -1,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 70,000.00 |
| Dec 31, 2022 | -155,000.00 |
| Sep 30, 2022 | -70,000.00 |
| Jun 30, 2022 | 171,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2020 | 319,000.00 |
| Sep 30, 2020 | -350,000.00 |
| Jun 30, 2020 | -15,000.00 |
| Mar 31, 2020 | 116,000.00 |
| Dec 31, 2019 | -363,000.00 |
| Sep 30, 2019 | 374,000.00 |
| Jun 30, 2019 | -237,000.00 |
| Mar 31, 2019 | 240,000.00 |
| Dec 31, 2018 | -579,000.00 |
| Sep 30, 2018 | -506,000.00 |
| Jun 30, 2018 | 2.13 Mn |
| Mar 31, 2018 | -531,000.00 |